All Major Solid Tumors with Brain Metastases
Cancer Type
Cerebrospinal Fluid (CSF)
Sample Type
8 Working Days
Turnaround Time ¹
ACTCerebra™ sequences 40 druggable genes to identify the most effective targeted therapies based on medical history.
Precision Medicine to Plan Better Treatment
Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.
Why ACT Genomics?
Humane Process
Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small CSF specimen is required for the simultaneous detection of 40 genes.
Ideal Treatment
Nominates proper targeted options for your brain metastases.
Smart Budgeting
Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.
Learn More
How Do You Win Over Brain Metastases?
In the same way that the bad guy always grabs the chance for a huge attack in the final scenes of a movie, brain metastases can arise in the latter part of cancer, and we want to win this battle. Quite a few cancer patients, especially those with lung and breast cancer, face the threat of having their cancer cells travel to the brain via blood vessels at the latest age of the disease, which results in brain metastases. The new advances in cancer treatment provides much hope to cancer patients, although better long-term survival rates and an increasing risk of brain metastases are two sides of the same coin, which makes conquering brain metastases an important focus. Performing cancer genomic profiling on a brain metastases specimen is a significant breakthrough in precision medicine, as it allows for accurate targeted therapy to overcome poor brain penetration and the avoidance of ineffective surgery, radiation therapy and chemotherapy.
Common Problems Associated with Cancer Treatment
- Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results
- Complications and metastases make it difficult to determine an appropriate drug
- Ineffective treatment and cancer relapse after targeted therapy
Diagnostic Solutions for Various Cancers
Through next-generation sequencing (NGS), ACTCerebra™ brain metastases genomic profiling decodes 40 genes to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.
ACTCerebra™ is suitable for breast, lung cancers and other solid tumors. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.
Who Is Suitable for ACTCerebra™?
- All major solid tumors with brain metastases
- Advanced, recurrent and metastatic cancer
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
